Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Moldova Contradiction in regulations could delay hemp cultivation ...
  • Germany Large-scale cannabis cultivation facility plans halted ...
  • Portugal Polytechnic launches medical cannabis course ...
  • Arizona - United States Bill to limit number of medical cannabis dispensaries goes to governor ...
  • New Mexico - United States Bill to allow medical use of psilocybin heads to governor ...
  • Luxembourg Study shows almost a sixth of cannabis users started after law passed ...
  • Germany NGOs want changes to cannabis law to protect consumers from addiction ...
  • Canada Health Canada updates cannabis/hemp web page with regulatory changes ...
  • Netherlands Coffee shops ask for delay of experimental phase of cannabis experiment ...
  • South Africa Ban on cannabis edibles sparks legal challenges ...
  • United States FDA issues warning to firm marketing intravenous form of CBD ...
  • Moldova First authorisation for hemp cultivation issued ...

CannIntelligence - complete coverage of novel food

CBD products are considered novel foods because there is no history of their consumption prior to May 1997. There is a stringent process for the authorisation of novel foods before they can be launched on the market, which includes an independent safety assessment to ensure the new products are safe for public consumption. All of our content that relates to CBD as a novel food can be accessed from this page.

New opportunities emerge in European cannabis markets

10th December 2024 - Press releases |

FOR IMMEDIATE RELEASE Business opportunities start to appear in European legal cannabis markets Recent initiatives on legalising cannabis in four European countries have put the spotlight on the commercial potential of the cannabis market. Germany, Malta, the Netherlands and Switzerland have all recently reformed their laws on recreational cannabis. The new rules differ from country to country, but they include » Continue Reading.

Affordability of medical cannabis depends on where you live

30th October 2023 - Press releases |

FOR IMMEDIATE RELEASE Affordability of medical cannabis depends on where you live Patients are paying dramatically different prices for medical cannabis depending on the country they live in, new research from CannIntelligence reveals. The CannIntelligence medical cannabis price tracker, launched last week, shows that prices for medical oil products in Germany are more than 300% higher than in Australia. For » Continue Reading.

Why US DEA decision does not mean the end for cannabinoids

27th February 2023 - Press releases |

FOR IMMEDIATE RELEASE Why US DEA decision does not mean the end for cannabinoids The US intoxicating hemp-derived cannabinoid (IHDC) market will not be ended by clarification from authorities saying delta-8 THC-O and delta-9 THC-O are illegal. Multiple reports have incorrectly suggested that the clarification from the US Drug Enforcement Administration (DEA), which was specifically on two THC acetate ester » Continue Reading.

CBD industry warned about new intoxicating cannabinoids shaking up the market

25th July 2022 - Press releases |

FOR IMMEDIATE RELEASE CBD industry warned about new intoxicating cannabinoids shaking up the market Consumers have an increasing appetite for cannabinoids that have a more intoxicating effect, which is shaking up the US CBD market, according to new research from CannIntelligence. A quarter of consumers are already buying CBD and delta-8 products and more than 50% are using them » Continue Reading.

Many high street CBD products must be removed from sale, research shows

12th April 2022 - Press releases , Resources |

FOR IMMEDIATE RELEASE Many high street CBD products must be removed from sale, research shows The majority of CBD oral products now on the UK market will have to be removed from sale, significantly affecting many retailers and consumers, new analysis from CBD-Intel suggests. CBD-Intel compared the recent Food Standards Agency (FSA) list of oral CBD products which are allowed » Continue Reading.

Italian company gains EU validation for synthetic CBD novel food application

8th July 2021 - News analysis |

The European Commission (EC) has validated a novel food application submitted by the Italian company Farmabios for a synthetic CBD. This is the first step to gaining novel food authorisation from the European Food Safety Authority (EFSA). The company said it had also submitted a similar dossier to the UK Food Standards Agency (FSA) and expects to receive validation there » Continue Reading.

Now that the deadline for applications has passed, when should enforcement action from the UK Food Standards Agency (FSA) be expected?

1st April 2021 - Blogs |

The FSA told CBD-Intel during a recent conference that – unsurprisingly – no actions would be taken until after the list of validated/administratively checked pending validation applications had been published. Thus far no date for the publication of the list has been put forward, but the speculation is that it will now more than likely be at least May before it » Continue Reading.

Was the UK FSA decision to make changes to the novel food application timeline really that unexpected?

25th March 2021 - Blogs |

The UK Food Standards Agency (FSA) has ruffled a few feathers by changing its criteria for allowing products to stay on the market. Instead of requiring a validated novel food submission, it now only requires a submission that has been administratively checked (essentially scanned over to make sure all required bits are present) – under the assumption that the application » Continue Reading.

Will the FSA-validated novel food submission list reveal commercially sensitive information?

11th March 2021 - Blogs |

There’s been some worry that the eventual list of brands with a novel food application validated by the UK Food Standards Agency (FSA) will reveal commercially sensitive information such as which brands are currently contracted to which ingredient or white-label goods suppliers. But the FSA has not indicated that such information would be included in any list. And there is » Continue Reading.

US CBD market worth $3bn by 2023

10th March 2021 - Press releases , Resources |

FOR IMMEDIATE RELEASE US CBD market worth $3bn by 2023 New CBD-Intel modelling predicts sharp increase in US CBD market value over next two years The US CBD market will break the $3bn mark in 2023, new CBD-Intel market data modelling predicts, with massive growth stemming from anticipated regulatory changes. CBD-intel predicts US Food and Drug Administration (FDA) rules providing a » Continue Reading.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.